Aclaris Therapeutics DEF 14A: Executive Compensation Details
Ticker: ACRS · Form: DEF 14A · Filed: Apr 24, 2025 · CIK: 1557746
| Field | Detail |
|---|---|
| Company | Aclaris Therapeutics, INC. (ACRS) |
| Form Type | DEF 14A |
| Filed Date | Apr 24, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, board-of-directors, annual-meeting, equity-awards
TL;DR
Aclaris Therapeutics DEF 14A out: Executive pay & equity awards for Dr. Walker & Dr. Manion detailed for 2022-2024.
AI Summary
Aclaris Therapeutics, Inc. filed a DEF 14A on April 24, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and board member information, including compensation for Dr. Walker and Dr. Manion for the fiscal years 2022, 2023, and 2024. It also reports on equity awards granted and vested for these individuals.
Why It Matters
This filing provides transparency into how Aclaris Therapeutics compensates its key executives and board members, which can influence investor decisions and perceptions of company governance.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing detailing executive compensation and board information, which typically does not introduce new material risks.
Key Numbers
- 2024 — Fiscal Year End (Reporting period for compensation details)
- 2023 — Fiscal Year End (Previous reporting period for compensation details)
- 2022 — Fiscal Year End (Earlier reporting period for compensation details)
Key Players & Entities
- Aclaris Therapeutics, Inc. (company) — Filer
- Dr. Walker (person) — Board Member / Executive
- Dr. Manion (person) — Board Member / Executive
- Mr. Balthaser (person) — Board Member / Executive
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide detailed information regarding the company's annual meeting of stockholders, including executive compensation, director information, and other corporate governance matters.
For which fiscal years are compensation details provided for Dr. Walker and Dr. Manion?
Compensation details are provided for the fiscal years 2024, 2023, and 2022 for both Dr. Walker and Dr. Manion.
What type of compensation is detailed in the filing for the named individuals?
The filing details equity awards granted and vested, including their fair value as of the prior year end and during the covered year.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted on April 24, 2025.
What is the business address of Aclaris Therapeutics, Inc.?
The business address is 701 Lee Road, Suite 103, Wayne, PA 19087.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 24, 2025 by Dr. Walker regarding Aclaris Therapeutics, Inc. (ACRS).